Newsroom

Three successful proposals receive funding from the DRIVE second Chemoproteomics and Mass Spectrometry Imaging call

Chemical proteomics and Mass Spectrometry Imaging (MSI) have emerged as key technologies to advance our understanding of the behavior and the pharmacological effects of small molecule drugs within a cellular environment. Within our DRIVE project call, European researchers were given the opportunity to harness the expertise of our partners in these areas.

Selected projects will aid the elucidation of underlying mechanisms of action of small molecule hit or tool compounds. Applicants could either apply for access to MALDI MSI technologies for quantitative analysis of compound disposition in disease-relevant tissue or for access to chemoproteomics tools to identify interacting proteins partners. We received promising proposals from Germany, Italy, Poland and Finland in the field of cancer, neurodegenerative diseases, cardiac fibrosis and malaria.

From these applications, two projects with high scientific potential were selected to gain access to chemoproteomics workflows at the Institute of Bioorganic Chemistry Polish Academy of Sciences, the Technical University of Munich and at the Department of Chemical Biology at the Helmholtz Centre for Infection Research. An additional project will benefit of collaborating with MALDI-imaging experts at the Center for Mass Spectrometry and Optical Spectroscopy at the Mannheim University of Applied Sciences, and at Department of Biotechnology and Nanomedicine at SINTEF.

We would like to thank all applicants for their interest and we look forward towards exciting new insights gained by the selected projects within this DRIVE call.